ReviewDer Pathologe2021
[COVID-19: effects on the lungs and heart].
Review in Der Pathologe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Long-Term Pulmonary Function in Healthcare Workers: A Spirometric Evaluation Three Years Post-COVID-19 Pandemic.Biomedicines · 2025Article
- Pulmonary function assessment after COVID-19 in vaccinated healthcare workers.Journal of occupational medicine and toxicology (London, England) · 2023Article
- Pulmonary and Systemic Pathology in COVID-19—Holistic Pathological AnalysesDeutsches Arzteblatt international · 2022Review
- COVID-19 and dys-regulation of pulmonary endothelium: implications for vascular remodeling.Cytokine & growth factor reviews · 2022Review
- Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19.International journal of molecular sciences · 2022Article
- Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.Frontiers in pharmacology · 2022Review
- Detection methods for SARS-CoV-2 in tissue.Der Pathologe · 2021Review
- Review
- Review
- [Methods of SARS-CoV-2 detection in tissue].Der Pathologe · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Viral respiratory diseases constitute the most common reasons for hospitalization with more than half of all acute illnesses worldwide. Progressive respiratory failure with pronounced diffuse alveolar damage has been identified as the primary cause of death in COVID-19. COVID-19 pneumonia shares common histopathological hallmarks with influenza (H1N1)-related ARDS, like diffuse alveolar damage (DAD) with edema, hemorrhage, and intra-alveolar fibrin deposition. The lungs with COVID-19 pneumonia revealed perivascular inflammation, an endothelial injury, microangiopathy, and an aberrant blood vessel neoformation by intussusceptive angiogenesis. While this pronounced angiocentric inflammation is likely be found - to varying degrees - in numerous other organs, e.g., the heart, COVID-19 is hypothesized to be not just a pulmonary, but rather a systemic "vascular disease."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.